To determine the most cost-effective Wet AMD treatment alternative in Mexico. METHODS: A decision tree with Bayesian approach and a Markov chain considering the probabilities of increasing, decreasing or maintaining visual acuity (VA) through eight health states based on VA from 20/20 to 20/400 due to the use of a pharmacological alternative, with a time horizon of 5 years and institutional perspective, were performed. The discounting rate was three percent for costs and benefits. Adverse events and their treatment costs, for every alternative were considered; costs, benefits and probabilities of transition data were estimated from the meta-analysis with available published literature, including the MARINA and ANCHOR studies, validated by a panel of Mexican experts through the Delphi technique. Study comparators examined were Ranibizumab (RAN), photodynamic therapy with Verteporfin (PDTV), pegaptanib sodium (PEG) and standard care (STD). Sensitivity analysis was one-way and probabilistic (acceptability curve, analysis of components for the ellipse method). RESULTS: Patients using Ranibizumab get more benefits (RAN = 2.71 QALY; PDTV = 2.03 QALY; PEG = 1.89 QALY; STD = 1.78 QALY), with the lowest total cost per treatment (RAN = $43,984 USD; STD = $63,531 USD; PDTV = $83,546 USD; PEG = $92,247 USD) and the lowest cost per QALY (RAN = $16,257 USD/QALY; STD = $35,749 USD/QALY; PDTV = $41,074 USD/QALY; PEG = $48,263 USD/QALY). Incremental analysis showed Ranibizumab to be the dominant alternative. Net benefits are greater with Ranibizumab independent of willingness to pay. Acceptability curves showed absolute superiority for Ranibizumab. The confidence interval of 95% with the ellipse method showed Ranibizumab to be dominant in 95% of the cases with a willingness to pay of $924USD. The sensitivity analysis on efficiency and costs of Ranibizumab in an interval of Ϯ50%, was robust with the base analysis. CONCLUSION: Ranibizumab is the most cost-effective Wet AMD treatment alternative; it offers the greatest benefits with the lowest cost. Sensitivity analyses showed the robustness of the base study.
PSS26 USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)
Spiegel BM 1 , Patel V 2 , Chiou CF 2 , Esrailian E 1 1 VA Greater Los Angeles Healthcare System; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 2 Amgen Inc, Thousand Oaks, CA, USA OBJECTIVE: Measure incremental cost-utility and budget impact of etanercept vs. infliximab in moderate-to-severe PSO with >10% body surface area involvement. METHODS: We used a Markov decision analysis to compare 2 strategies for PSO: etanercept label dose (50 mg BIW x12 wks, then 25 mg BIW); and infliximab label dose (5 mg/kg IV at wks 0, 2, and 6, then 5mg/kg Q8W). We derived 60 probability estimates through systematic review of the literature and labels, varying each of these estimates in each sensitivity analysis. We adopted an MCO payer's perspective, and included cost estimates for a comprehensive list of related resources as determined by Medicare and the Red Book. Qulaity-adjusted life-years (QALYs) were estimated by applying utilities from the literature to reported efficacy as measured by PASI scores. We calculated the incremental cost per QALY gained and incremental per-member per month (PMPM) budget impact in a hypothetical MCO of 1 million lives (assuming a 1% prevalence of moderate-to-severe PSO). We discounted costs and effects at 3% First year persistence measures: whether last fill had sufficient days supply to achieve medication possession at year's end; number of days for which index agent was available (days covered). Possible inconsistencies between quantity dispensed and reported days supply addressed by multiplying claimed days supply with alternative measures from the literature. Models of associations between index agent and medication possession (logistic regression) and days covered (linear regression) were adjusted for gender, age, and previous ocular hypertension diagnosis. RESULTS: A total of 7783 patients met inclusion criteria (LAT, n = 4994; BIM, n = 1464; TRAV, n = 1415). Overall medi-
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